Press enter to see results or esc to cancel.

Vivet Therapeutics

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. It is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long-term expression. Vivet’s …

Continue Reading

Minoryx Therapeutics

Minoryx Therapeutics is a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102) — a novel, brain penetrant and selective PPAR gamma agonist — is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. In …

Continue Reading